Individual Article: Updated Review of Topical Pharmaceuticals and Complementary and Alternative Medications for the Treatment of Onychomycosis in Both General and Special Populations in the United States.
J Drugs Dermatol
; 22(9): SF378719-SF378719s10, 2023 Sep 01.
Article
in En
| MEDLINE
| ID: mdl-37683068
ABSTRACT
Onychomycosis is a prevalent condition affecting the United States and global population. Treatment options are limited, with only 3 topical anti-fungal medications garnering approval in the US within the last 25 years ciclopirox, tavaborole, and efinaconazole. The economic impact and quality of life burden due to onychomycosis are high. Here we provide an up-to-date review of all approved topical anti-fungal therapies for toenail onychomycosis. We discuss treatment efficacies, pharmacology, and use in special populations, as well as current evidence for complementary and alternative medicine. J Drugs Dermatol. 2023;229(Suppl 1)s5-10.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Onychomycosis
Aspects:
Patient_preference
Limits:
Humans
Country/Region as subject:
America do norte
Language:
En
Journal:
J Drugs Dermatol
Journal subject:
DERMATOLOGIA
Year:
2023
Document type:
Article